TriangleObecabtagene Autoleucel (NCT07400029)
Obecabtagene Autoleucel trial for Acute Lymphoblastic Leukemia (NCT07400029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients with CD19-positive B-cell acute lymphoblastic leukemia in first remission without measurable residual disease. Patients 40+ qualify; selected patients aged 30–39 need high-risk comorbidities or poor chemotherapy tolerance.
The idea: obecabtagene autoleucel uses the patient's modified T cells to target CD19. Cells are collected by apheresis, then infused after lymphodepleting chemotherapy. Remission must be documented within four months of starting initial treatment. Both Philadelphia groups participate; researchers track relapse.
This phase 2 study plans 40 patients. Ioannis Kalogirou Valtis leads at Memorial Sloan Kettering; nine US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.